35 results about "Uracil nucleoside" patented technology

A method and composition for the treatment, prevention and / or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides 5-aldehydo-uracil nucleosides and derivatives thereof, and methods of administration thereof to increase the virus mutation rate in a virally infected cell.

The invention discloses a method for synthesizing uridine. The method comprises the following steps of: adding uracil, D-ribose and a catalyst into a condensing agent, stirring and heating the mixed solution for reaction until the reaction temperature is between 20 and 80 DEG C, clarifying the mixed solution, keeping the temperature of the mixed solution for reaction for 3 to 25 hours, distilling the mixed solution at the normal pressure until the volume of the mixed solution is reduced to one fourth to one third of the original volume, after reaction, distilling the mixed solution under a reduced pressure until no liquid comes out, adding an organic solvent of which the mass is 3 to 8 times that of the D-ribose into the obtained product, stirring the mixed solution for dissolution,refluxing the mixed solution for 1 to 2 hours while stirring, cooling the mixed solution to the temperature of between 0 and 5 DEG C, crystallizing the mixed solution for 1 to 6 hours, filtering the mixed solution, and drying the filter cakes to obtain the uridine. The yield of the uridine is over 78 percent, and the HPLC of the uridine is over 99.35 percent. The method has the advantages of simple and reasonable process, good stability, safe production process, convenient operation and the suitability for industrialization.

The invention is a biomolecule curing tumours, its character: in a special sequence, it is a dichain RNA molecule with 23 basic groups. Its molecular structure contains adenine nucleotide A, guanosine G, cytidine C and uridine U. Its beneficial effects: 1, obvious effect of prohibiting tumour growth and high selectivity, able to overcome poisonous side effect of quinoline drug; 2, good stability; 3, effect amplification; 4, easy to prepare. It can be used to prepare clinical antitumor drug, where the drug form is any one of water solution injection, liposome soliquoid injection and latex.

The invention relates to the technical field of metal processing and particularly discloses a modified GO (graphene oxide), an application thereof, a drawing solution containing the modified GO and apreparation method of the modified GO and the drawing solution. The modified GO is prepared by the reaction of uracil nucleoside and an intermediate product obtained by the reaction of sulfhydryl siloxane and GO, the mass ratio of the sulfhydryl siloxane to GO is 5-10: 1, the mass ratio of the intermediate product to the uracil nucleoside is 1: 1-2, and the drawing solution contains the modified GO. The drawing solution has low sulfur content and excellent extreme pressure wear resistance, corrosion resistance and storage stability.

The invention discloses a preparation method of α-uridine nucleoside. The method comprises the steps of: after alkaline hydrolyzing the compound shown in formula C, acid treatment is carried out to obtain the compound shown in formula A; the preparation method of the compound shown in formula C comprises the steps of: making The silylated uracil is condensed with the di-esterified ribose sugar shown in formula B to obtain the compound shown in formula C.

A method and composition for the treatment, prevention and / or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

The disclosed six-membered carbocyclic nucleoside analogues comprise: adenosine analogue, guanosine analogue, carnine analogue, mercaptopurine riboside analogue, cytidine analogue, 5-fluorocytidine analogue, uridine analogue, 5-fluorouridine analogue, and thymidine analogue as well as their acceptable salts formed by equimolar acid in pharmacy. Wherein, the opposite five-step synthesis method using the pinitol, acetone, methane sulfonyl chloride, p-toluenesulfonyl chloride, benzene sulfochloride, and nucleoside base as materials; the pyridine, water, glacial acetic acid, absolute methanol, DMSO, N, N-DMF as the solvent; the p-toluenesulfonic acid, 2, 2-dimethoxylpropane, anhydrous NaSO4, NaHCO3, triethylamine, and anhydrous K2CO3 as the catalyst. This invention restrains specially the replication of HIV and herpesvirus.

The invention discloses an oleanolic acid-uridine conjugate, a preparation method thereof, and application of the oleanolic acid-uridine conjugate in the field of pharmacy. The applicant discovers that the oleanolic acid-uridine conjugate has much higher anti-tumor activity than oleanolic acid, a matrix of the oleanolic acid-uridine conjugate, and a lead compound is provided for developing new anti-tumor drugs. The conjugate has a structure of the general formula (II) shown in the specification.

The invention relates to a large-scale serum-free culture method for rhIL-12 engineering cells, which comprises the following step of: inoculating rhIL-12 engineering cells in a logarithmic phase into a serum-free and protein-free medium for culture, wherein the medium is a CD CHO liquid medium comprising sodium pyruvate at the final concentration of 0.8 to 1.2mM, hypoxanthine at the final concentration of 0.075 to 0.125mM, thymidine at the final concentration of 0.012 to 0.020mM, adenosine at the final concentration of 0.5 to 0.9mg / L, guanosine at the final concentration of 0.5 to 0.9mg / L, cytidine at the final concentration of 0.5 to 0.9mg / L, uridine at the final concentration of 0.5 to 0.9mg / L, L-glutamine at the final concentration of 0.4 to 0.8mg / L, L-asparagine at the final concentration of 0.4 to 0.8mg / L, L-proline at the final concentration of 1.5 to 2.0mg / L and non-essential amino acid at the final concentration of 0.08 to 0.125mM. The invention also provides a medium used in the method. By the medium and the culture method, a high-yield and high-activity recombinant human interleukin-12 can be obtained.

The invention relates to a method for enzymatically synthesizing nicotinamide uracil dinucleotide and its application. The nicotinamide mononucleotide adenosyltransferase mutant is used as a catalyst to catalyze the coupling reaction of nicotinamide mononucleotide and uridine nucleoside triphosphate to prepare nicotinamide uracil dinucleotide. Express the coding gene of nicotinamide mononucleotide adenylyltransferase mutant in microbial cells, engineered bacteria use endogenous metabolites to synthesize nicotinamide uracil dinucleotide, and intracellular nicotinamide uracil dinucleotide can be As a coenzyme, it selectively mediates redox reactions and increases the yield of target metabolites. In a typical example, succinic acid production was increased by 35%.